

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



開拓藥業有限公司*

KINTOR PHARMACEUTICAL LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 9939)

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 30 JUNE 2022

Reference is made to the circular (the “**Circular**”) and the notice (the “**Notice**”) of the annual general meeting (the “**AGM**”) of Kintor Pharmaceutical Limited (the “**Company**”) both dated 30 May 2022. Unless otherwise defined herein, the capitalised terms used herein shall have the same meaning as those defined in the Circular.

POLL RESULTS OF THE AGM

The Board is pleased to announce that at the AGM held on 30 June 2022, all the proposed resolutions as set out in the Notice were duly passed by the Shareholders by way of poll.

As at 30 June 2022, the total number of issued Shares entitling the Shareholders to attend and vote for or against the resolutions at the AGM was 387,589,600. There were no restrictions on any Shareholders of the Company to cast votes on any of the proposed resolutions at the AGM. There were no Shares entitling the Shareholders to attend and abstain from voting in favour of the resolutions proposed at the AGM as set out in Rule 13.40 of the Listing Rules. No Shareholder was required under the Listing Rules to abstain from voting on any of the resolutions proposed at the AGM. None of the Shareholders have stated their intention in the Circular to vote against or abstain from voting on any of the proposed resolutions at the AGM.

The Company's Hong Kong Share Registrar, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer for the vote-taking at the AGM. The poll results in respect of all the resolutions proposed at the AGM are as follows:

Ordinary Resolutions		Number of votes cast (%)		
		For	Against	
1.	To receive, consider and adopt the audited consolidated financial statements of the Company and its subsidiaries and the reports of the directors of the Company and independent auditor for the year ended 31 December 2021.	164,899,275 (100.000000%)	0 (0.000000%)	
2.	(a)	(i) To re-elect Dr. Youzhi TONG as an executive Director.	164,569,459 (99.799989%)	329,816 (0.200011%)
		(ii) To re-elect Ms. Yan LU as an executive Director.	164,894,324 (99.996998%)	4,951 (0.003002%)
		(iii) To re-elect Mr. Weipeng GAO as a non-executive Director.	164,894,324 (99.996998%)	4,951 (0.003002%)
		(iv) To re-elect Ms. Geqi WEI as a non-executive Director.	164,894,324 (99.996998%)	4,951 (0.003002%)
		(v) To re-elect Mr. Chengwei LIU as a non-executive Director.	164,840,256 (99.964209%)	59,019 (0.035791%)
		(vi) To re-elect Mr. Wallace Wai Yim YEUNG as an independent non-executive Director.	164,899,275 (100.000000%)	0 (0.000000%)
	(b)	To authorise the Board to fix the remuneration of the Directors.	164,899,275 (100.000000%)	0 (0.000000%)
3.	To re-appoint Messrs. PricewaterhouseCoopers as the auditor of the Company until the conclusion of the next annual general meeting of the Company and to authorise the Board to fix its remuneration.	164,899,275 (100.000000%)	0 (0.000000%)	

Ordinary Resolutions			Number of votes cast (%)	
			For	Against
4.	(A)	To give a general mandate to the directors of the Company to allot, issue and deal with additional shares not exceeding 20% of the total number of issued shares of the Company.	162,244,506 (98.390066%)	2,654,769 (1.609934%)
	(B)	To give a general mandate to the directors of the Company to repurchase shares not exceeding 10% of the total number of issued shares of the Company.	164,899,275 (100.000000%)	0 (0.000000%)
	(C)	To extend the authority given to the directors pursuant to ordinary resolution no. 4(A) to issue shares by adding to the number of issued shares of the Company the number of shares repurchased under ordinary resolution no. 4(B).	162,286,006 (98.415233%)	2,613,269 (1.584767%)

For details of the above resolutions, please refer to the Circular.

As more than 50% of the votes were cast in favour of each of the above resolutions, all the above resolutions were duly passed by the Shareholders as ordinary resolutions of the Company.

All directors of the Company attended the AGM.

By order of the Board
KINTOR PHARMACEUTICAL LIMITED
Dr. Youzhi Tong
*Chairman of the Board, Executive Director and
Chief Executive Officer*

Hong Kong, 30 June 2022

As of the date of this announcement, the executive Directors are Dr. Youzhi Tong and Ms. Yan Lu; the non-executive Directors are Mr. Weipeng Gao, Ms. Geqi Wei and Mr. Chengwei Liu; and the independent non-executive Directors are Dr. Michael Min Xu, Mr. Wallace Wai Yim Yeung and Prof. Liang Tong.

* For identification purpose only